Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m

New Executive Team Members Also Announced

Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.

Neon sign illuminating "VENTURE"
Eikon's series B brings the company's funding to date to $668m • Source: Alamy

Eikon Therapeutics, Inc. came out of stealth mode with an icon at its helm last year and a venture capital mega-round to fund development of a technology platform that uses super-resolution microscopy and advanced engineering to discover novel drugs. Now, the company said on 6 January, it has raised a much bigger mega-round – $517.8m in series B funding – to accelerate the buildout of its platform, rapidly scale its growth and advance multiple undisclosed drug discovery programs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By 

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.